Boehringer Ingelheim signs licence agreement with XstalBio
XstalBio of Glasgow, Scotland, has signed a licence agreement with Boehringer Ingelheim, Germany, for its pioneering protein-coated microcrystal (PCMC) technology. As part of the agreement, XstalBio will receive milestone payments and manufacturing rights to the jointly developed manufacturing process, but no figures were disclosed.
XstalBio of Glasgow, Scotland, has signed a licence agreement with Boehringer Ingelheim, Germany, for its pioneering protein-coated microcrystal (PCMC) technology. As part of the agreement, XstalBio will receive milestone payments and manufacturing rights to the jointly developed manufacturing process, but no figures were disclosed.
XstalBio, a spin-out from the Universities of Strathclyde and Glasgow, is a formulator of protein-based drugs engineered for advanced drug delivery applications.
Boehringer Ingelheim believes the collaboration will provide improved methods for the formulation and delivery of biomolecules.
XstalBio's chief scientist, Dr Barry Moore, said: "The technology provides a highly differentiated method for preparing biomolecules as stable, solid formulations, with the particles capable of being engineered for delivery in a range of formulations via various routes of administration".
Both partners will jointly develop and scale-up the PCMC technology for GMP manufacturing at pilot scale.